APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer

Lung cancer is the leading cause of cancer-associated mortality. Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancers. The overall survival for NSCLC is dismal, with a 5-year survival of <5% for patients. Thus, identifying an effective biomarker for early diagnosis of lung cancer is the first essential step to reduce mortality. It has been recognized that certain inflammatory and immune responses are important in lung cancer development and prevention. The present study demonstrated that, in NSCLC, a proliferation-inducing ligand (APRIL), B-cell maturation antigen (BCMA)and transmembrane activator and CAML interactor (TACI) proteins are abnormally expressed by immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting. In addition, the expression of APRIL, BCMA and TACI were observed to be involved in extracellular signal-regulated kinase (ERK)1/2 activation in A549 cells. Overall, the present study provides evidence that APRIL and its receptors, BCMA and TACI, may play roles in the biological processes of NSCLC tumors through the ERK1/2 signaling pathway.

[1]  M. Hahne,et al.  APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. , 2015, Carcinogenesis.

[2]  Shi-fang Sun,et al.  TGF-β1, IL-6, and TNF-α in Bronchoalveolar Lavage Fluid: Useful Markers for Lung Cancer? , 2014, Scientific Reports.

[3]  Haojun Xie,et al.  Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis , 2014, Tumor Biology.

[4]  M. Kampa,et al.  BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 Proteins Are Related to Human Glioma Tumor Grade: Immunohistochemistry and Public Microarray Data Meta-Analysis , 2013, PloS one.

[5]  Gentao Liu,et al.  Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway. , 2013, Toxicology.

[6]  Zimin Liu,et al.  Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells , 2013, Journal of chemotherapy.

[7]  M. Hensey,et al.  A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service , 2013, Irish Journal of Medical Science.

[8]  M. Kampa,et al.  APRIL Binding to BCMA Activates a JNK2–FOXO3–GADD45 Pathway and Induces a G2/M Cell Growth Arrest in Liver Cells , 2012, The Journal of Immunology.

[9]  Xiaodong Li,et al.  TNF receptor-associated factor 6 in advanced non-small cell lung cancer: clinical and prognostic implications , 2012, Journal of Cancer Research and Clinical Oncology.

[10]  M. Hahne,et al.  The TNF family member APRIL promotes colorectal tumorigenesis , 2012, Cell Death and Differentiation.

[11]  M. Kampa,et al.  Detection of The TNFSF Members BAFF, APRIL, TWEAK and Their Receptors in Normal Kidney and Renal Cell Carcinomas , 2011, Analytical cellular pathology.

[12]  Yun-Wei Lin,et al.  Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase–AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non–Small Cell Lung Cancer Cells , 2009, Molecular Cancer Research.

[13]  B. Klein,et al.  APRIL is overexpressed in cancer: link with tumor progression , 2009, BMC Cancer.

[14]  F. Herrmann,et al.  Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. , 2008, European journal of cancer.

[15]  Lin Chen,et al.  Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. , 2008, Oncology reports.

[16]  S. Han,et al.  Protein kinase C‐ERK1/2 signal pathway switches glucose depletion‐induced necrosis to apoptosis by regulating superoxide dismutases and suppressing reactive oxygen species production in A549 lung cancer cells , 2007, Journal of cellular physiology.

[17]  G. Sauter,et al.  The source of APRIL up‐regulation in human solid tumor lesions , 2006, Journal of leukocyte biology.

[18]  Astrid Dempfle,et al.  TNF-α, TNF-β, IL-6, and IL-10 Polymorphisms in Patients with Lung Cancer , 2005, Disease markers.

[19]  S. Vicent,et al.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours , 2004, British Journal of Cancer.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  Y. Wu,et al.  [The preoperative and postoperative changes of T lymphocyte subsets and TNF in patients with locally advanced lung cancer.]. , 1999, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[22]  J. Tschopp,et al.  APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth , 1998, The Journal of experimental medicine.

[23]  L. Tanoue,et al.  The Stage Classification of Lung Cancer , 2013 .

[24]  E. Chyczewska,et al.  TNF-alpha, IL-1 and IL-6 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC). , 1997, Roczniki Akademii Medycznej w Bialymstoku.